Trump Administration Teases MFN Drug Pricing Rule as Commitment Deadline Looms for Companies

Trump administration; Most-Favored-Nation (MFN) pricing; drug pricing; executive order; pharmaceutical manufacturers; Medicaid; direct-to-consumer sales; price parity; commitment deadline; tariffs; international reference price

Trump Administration Launches Tariff Probe into Medtech and Pharmaceutical Industries

Trump administration; tariffs; medtech industry; pharmaceutical imports; Section 232 investigation; semiconductor tariffs; national security; supply chain; manufacturing; medical devices

Trump Administration Weighs Severe Restrictions on US Pharmas Licensing Chinese Medicines

Trump administration; Chinese medicines; executive order; pharmaceutical industry; licensing restrictions; national security; lobbying; Pfizer; AstraZeneca; biotech; drug manufacturing; FDA review

US to Stockpile Critical Drug Ingredients Under Latest Trump Executive Order

Trump; Executive Order; drug ingredients; pharmaceutical supply chain; Strategic Active Pharmaceutical Ingredients Reserve; ASPR; domestic manufacturing; national security; essential medicines